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Abstract 
Purpose:  Quality of life in people with epilepsy depends on balancing protection from risks and 
avoiding unnecessary restrictions.  The Epilepsy Risk Awareness Checklist (ERAC) was developed to 
summarise an individƵĂů ?ƐƐĂĨĞƚǇ ?ŚĞĂůƚŚĐĂƌĞĂŶĚƋƵĂůŝƚǇŽĨůŝĨĞ and to facilitate communication 
between professionals. Although effective, the existing Checklist required quantification and 
shortening to increase its utility, particularly as a longitudinal tool for measuring and communicating 
changes over time. 
Methods:  5 clinical experts, 3 people with epilepsy and 5 carers assessed the importance of each 
item on the ERAC questionnaire in a two-round Delphi survey. The refined Epilepsy Risk Awareness 
scale (ERA scale) was piloted in 30 patients to obtain an overall and sub-scale score for personal 
safety, health care, and quality of life domains, and was compared with the validated Seizure 
Severity Scale and Epilepsy Self-Management Scale.  
Results:  ERAC was shortened from 69 to 48 items to take 15-20 minutes for completion. Pilot results 
showed good internal consistency for the overall ERA scale, for the Personal Safety and Health Care 
subscales, but less for the Quality of Life subscale.  There was strong association between ERA scale 
and the Epilepsy Self-Management Scale, but little relationship with Seizure Severity Scale scores, 
which focus on individual seizures. User ratings were high. 
Conclusions: The ERA scale has been shortened and quantified. It shows potential for quantifying 
the risks and safety profile in people with epilepsy. These pilot results will be further tested for intra-
rater variability and utility.  
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Epilepsy, one of the most common neurological disorders, with a lifetime prevalence of 2 - 5%  [1], 
has major medical and psychosocial consequences [2]. It carries a significant risk of injury and is 
sometimes fatal, most commonly through sudden unexpected death in epilepsy (SUDEP) [3-6]. The 
fear of having a seizure can isolate the patient and limit both work and leisure activities [7-9].  
Maximising quality of life depends on reducing seizure frequency, and appropriate personalised 
safety advice without undue restriction [4,9-11]. Scales are an important and established tool in 
neurological practice, for example the Glasgow Coma scale [12], the FAST score for stroke [13] and 
the Waterlow score for pressure areas [14].  Formal risk assessment is recommended for those with 
epilepsy, including during daily activities (such as washing, preparing food), assessment of the social 
situation, and degree of independence [1]. Healthcare professionals, particularly  epilepsy nurses 
[15], have had limited evidence-based standardised measures of risk despite their recognised 
importance [16-18]. To fill this need, the Epilepsy Risk Awareness Checklist (ERAC) was developed by 
the authors as an evidence based tool recording personal safety, health care and quality of life 
related to epilepsy. Face and content validity of the ERAC has been established in the pre-pilot work 
[19]. 
The aim of this study was to streamline and quantify the ERAC. Specifically, the study examined 
whether any of the questions on the ERAC tool were redundant, to shorten the Checklist, and to 
provide a weighted numerical score for each item and a total risk score for adults with epilepsy.  
 
Methodology 
The study incorporates a Public Patient Involvement component (four carers and one patient with 
epilepsy) who reviewed the study protocol, the participant information sheet (PIS), consent form 
and the Delphi and pilot questionnaires. Patient involvement [20] allowed the study team to review 
the significance of risk management from a patient and carer perspective, to examine ease of use of 
the Checklist. The user consensus was that the ERAC checklist needed to be shorter and easier to 
complete.  
A mixed methods [21] approach to tool development was used for the Delphi and pilot stages, 
drawing on established techniques of confirming items, validating that each item is a measure of risk 
and undertaking reliability and construct validity testing. The study was carried out within the 
following two stages: 
 
x Stage 1: Delphi Questionnaire  
Clinical experts, adults with epilepsy and carers of people with epilepsy were recruited via clinical 
networks and epilepsy organisations to assess each item on the ERAC questionnaire. The objective 
was to reduce the number of items by one third to around 50 so that the questionnaire could be 
completed in about 15 minutes. The Delphi survey approach was used to reach consensus on health 
related issues [22]. The survey was conducted in two rounds. The first round investigated the 
perceived usefulness of the items in the ERAC questionnaire. Panel members were asked to rate the 
usefulness of each item to the concept of risk in epilepsy on a Likert scale [23] from 1 (unimportant) 




to 5 (essential).  Participants could also rate an item as completely redundant (0) and suggest new 
items that they thought might be important.  
Using the method of Paschoal [24], each item was scored by calculating the mean rating (redundant 
items were taken to be zero), and these scores used to rank the items based on their perceived 
usefulness.  Items in the lowest third of the scores were removed; new items suggested by more 
than 20% of the participants were added to the list. Items rated as borderline by the Delphi panel 
were discussed by the clinical members of the team and removed if regarded as unhelpful.  
In Round 2 of the Delphi questionnaire, the same participants were asked to rank each of the 
remaining original items from the ERAC questionnaire along with any new suggested items using a 
Likert scale of 1 to 4. The ranked items were divided into quartile bands based on the sum of the 
Likert scores given by the participants. In the calculation of the ERAC totals, items in the highest 
quartile were assigned a weight of 4, those in the third quartile a weight of 3, those in the second 
quartile a weight of 2, with items in the lowest quartile having a weight of 1. 
 
x Stage 2: Reliability and construct validity - Piloting  
Following the Delphi phase, the refined ERAC questionnaire (ERA scale) was piloted with 30 patients, 
using sample size calculation methodology of Lancaster [25]. The weights were used to score each 
item. A positive response, indicating good risk assessment, received the item weight and a negative 
response scored zero. These values were used to calculate an overall ERA scale score and a total for 
each subscale (personal safety, health care, and quality of life), high scores indicating low risk. The 
pilot study questionnaire also contained the Seizure Severity Scale (SSS) [26], the Epilepsy Self-
Management Scale (ESMS) [27] and questions on age, gender, marital status, religion, current 
employment, education, and number of antiepileptic medicines currently prescribed. Participants 
were asked to rate the questionnaire (on a scale from 0 to 10) in terms of its usefulness and how 
easy it was to complete. 
ERA scale total scores were tested for internal reliability using Cronbach ?Ɛ alpha coefficient (D) [28]. 
Construct validity for the ERA scale questionnaire was assessed by comparing total scores with those 
from the validated SSS and ESMS using the Spearman rank correlation coefficient (rs). In addition, 
the level of internal consistency was calculated for each subscale of the ERA scale. Internal 
consistency was considered to be satisfactory with a Cronbach ?Ɛ alpha coefficient of at least 0.7 [29]. 
The SSS and ESMS were selected as appropriate comparators for construct validity as the concept of 
risk is inherent in both. Seizure severity is related to the risk of seizure and its sequelae.  Self-
management is related to risk management ƚŚƌŽƵŐŚƚŚĞƉĞƌƐŽŶ ?ƐĂďŝůŝƚǇƚŽŵĂŶĂŐĞƚŚĞŝƌĞƉŝůĞƉƐǇ
without unnecessary medical attention. The ERA scale aims to quantify epilepsy risk and is therefore 
a different construct that is theoretically related to these measures but not the same.  
For the ERA scale items,  “ŶŽƚĂƉƉůŝĐĂďůĞ ?ĂŶĚŵŝƐƐŝŶŐ responses were scored as zero, a cautionary 
approach being taken so that a high score depended on positive data. For SSS data with missing 
information, the total score was estimated as the mean of the highest and lowest possible values, 
unless the range of possible totals was greater than 10. Totals that were too uncertain to be 
estimated were recorded as missing. With the ESMS, each of the five subscales (management of 
medication, information, safety, seizures, and lifestyle) was checked for missing values. If a subscale 




contained only one missing value, this was estimated by the median of the other subscale 
observations. Using this method, the ESMS total could be estimated in cases where all subscales 
contained no more than one missing value. Analyses were performed using SPSS Version 20  [30]. 
Ethics Approval 
Ethics approval was through the NHS REC on 10/07/2015 (ID:15/NW/0607). The study was 
conducted in accordance with the guidelines of Good Clinical Practice, and data handling was in 
accord with the Data Protection Act 1998 [31]. 
 
Results  
x Delphi  
The panels recruited for the Delphi exercise consisted of 3 patients, 5 carers and 5 professionals. 
Average age was 46 years and 9 (82%) were female. 
In Round 1 of the Delphi exercise, averaged usefulness scores across the 69 ERAC items ranged from 
 ? ? ? ? ?ĨŽƌ “ƌĞŝŶũƵƌŝĞƐƵŶůŝŬĞůǇƚŽŽĐĐƵƌǁŚŝůĞƉƌŽƚĞĐƚŝǀĞĚĞǀŝĐĞƐĂƌĞŝŶƉůĂĐĞ ? ? ?ƚŽ ? ? ? ? ?ĨŽƌ “/Ɛ
neurological (epilepsy) consultation or management obtained when seizures are not well controlled 
ŽƌǁŚĞŶƐŝŐŶŝĨŝĐĂŶƚĚƌƵŐƐŝĚĞĞĨĨĞĐƚƐĂƌĞƉƌĞƐĞŶƚ ? ? ? ?The number was reduced to 51 by retaining only 
the items with a score of greater than 3.6. Seven of the 8 items on the theme of social activities of 
the patient with family/ carers were removed at this stage. Each of the new items suggested by 
panel members were proposed by less than 20% (3) of those surveyed so none were included.  
Three items that received a mean score of less than 3.8 from the Delphi panel were thought to be 
either unnecessary or irrelevant by the team and were removed ?dŚĞƐĞǁĞƌĞ ? “/ƐƚŚĞƐĞŝǌƵƌĞƚǇƉĞ
classified according to the International ClassificĂƚŝŽŶŽĨƉŝůĞƉƚŝĐ^ĞŝǌƵƌĞƐ ? ? ?ƚŽŽtechnical for 
routine assessment) (panel mean 3.77);  “ŽĞƐƚŚĞĐůŝĞŶƚ ?ƉĂƚŝĞŶƚĂƚƚĞŶĚƉĂĞĚŝĂƚƌŝĐŝĂŶ ? ? ?ŝrrelevant 
for adult patients) (panel mean 3.62);  “ŽĞƐŝŶĚŝǀŝĚƵĂůĂŶĚĨĂŵŝůǇ ?ĐĂƌĞƌƐƵƐĞƉƵďůŝĐƚƌĂŶƐƉŽƌƚ ?  
(panel mean 3.62). The shortened version of the ERAC questionnaire consisted of 48 items, 14 from 
the Personal Safety section, 25 from the Health Care section, and 9 on Quality of Life. The goal of a 
reduction in the number of ERAC items to around 50 was therefore achieved. 
For Round 2 of the Delphi exercise, the quartile bands were derived from the completed 
questionnaires of the 10 original respondents who participated at this stage (3 patients, 3 carers, 4 
professionals). The total weighting scores were restricted to whole numbers so exact quartiles could 
not be derived. However, similarly sized bands were obtained. Of the 48 items, 11 received the 
lowest weight of 1, 12 received a weight of 2, 11 received a weight of 3, and the remaining 14 items 
the highest weight of 4. The maximum possible ERA scale total score for these bands (124) was close 
to that for exact quartiles (120) indicating that the inequality of the band sizes would have little 








For the 30 participants recruited in the pilot study, average age was 37 years and 20 (67%) were 
female. Most patients (17, 59%) were single, with 6 (21%) married and 4 (13%) in a partnership. Half 
(15, 52%) were in employment and 11 (55%) had either a university degree or a diploma. The 
number of anti-epileptic drugs prescribed had a median of two. For half (50%) of the participants 
(15) a seizure usually lasted 1-10 minutes, and for 11 patients 10 seconds to 1 minute (37%).   
There were relatively few missing observations. Data for the Seizure Severity Scale were complete 
and an ERA scale score could be calculated for each participant. For the Epilepsy Self-Management 
Scale, the total score was missing for only 2 (7%) of the patients. 
Internal consistency was acceptable for the ERA scale questionnaire as a whole (D = 0.795), the 
Personal Safety subscale (D = 0.708) and Health Care (D = 0.705). However, for the Quality of Life 
subscale, internal consistency was low (D = 0.259). 
Construct validity was high for the ERA scale overall (Fig.1) when compared to the ESMS total scores 
(rs = 0.781) but was non-existent (Fig.2) in a comparison of the ERA scale with the Seizure Severity 
Scale (rs = -0.100). 
Feedback regarding the questionnaire was good. Participants gave it a mean score of 7.5 for 
usefulness and a mean score of 7.9 for how easy the questionnaire was to understand. 
Figure 1: ERA scale vs. Epilepsy Self-Management Scale     
 
 
Figure 2: ERA scale vs. Seizure Severity Scale   








The ERA scale is a quantified tool (Appendix) for determining individual safety and risk in people with 
epilepsy. The scale had good overall internal consistency and acceptable consistency for personal 
safety and healthcare sub scales. Internal consistency for quality of life was poor, possibly because 
the questions are too diverse; and further refinement of this section will be needed.  User 
satisfaction was high.  
 
Association with other scales 
The construct validity between the ERA scale and the Epilepsy Self-Management Scale was high. The 
ERA scale showed little correlation with the Seizure Severity Scale, despite the SSS being validated. 
This lack of association is probably because the Seizure Severity Scale places a very high weighting 
on the time to complete recovery from a seizure (which is not necessarily related to safety or risk). 
Additionally, the Seizure Severity Scale places weighting on automatisms, which may or may not 
correlate with risk. Automatisms include potentially risky behaviour (such as running onto the road 
or utilising nearby dangerous objects) and benign motor activity (such as orobuccal automatisms).  
 
 





The limitations of the study include the inherent difficulties of quantifying subjective experience 
particularly in terms of quality of life, a crucial but difficult concept to measure. A larger sample may 
have generated a wider range of statements from patients and carers with different types of 
epilepsy. We did not include carers of people with epilepsy who had lost a relative with SUDEP or 
from other causes of mortality that may have had some specific impact on risk. 
 
Future developments 
The ERA scale provides rapid assessment of immediate risk, and longitudinal assessment of changes, 
essential for improving epilepsy management in patients, in particular, those with refractory 
epilepsy. It also facilitates communication between services. This is particularly important when a 
patient faces an acute change in their health (such as infection, operations, new co-morbidities), 
care provider or responsible healthcare professional. A strength of the ERA scale is that patient 
centred methods were used to ensure patient involvement in research and management at all 
stages, not only at the final stage of their treatment [32]. Use of the Delphi method also ensured 
that the ERA scale is pragmatically acceptable as well as statistically valid.  
 
Future development of the ERA scale is planned with a test re-test investigation involving 100-200 
patients who will complete the ERA scale with their nurse or carer at baseline and at two months of 
follow-up. Scores will be analysed for repeatability using intra-class correlation coefficients. The final 
stage of the research will be to assess the utility of the ERA scale in measuring long-term outcomes 
of risk management interventions for people with epilepsy. 
 
Conclusions 
Through an iterative process that involved the Delphi technique a pragmatically acceptable and valid 
risk assessment scale, the ERA scale, has been developed for use with patients with epilepsy. Whilst 
the scale needs a test re-test assessment, it has potential to estimate current risk. This will enable 
clinicians to stratify risk and prioritise those most in need of intervention. To our knowledge, the ERA 
scale is the only valid scale available for this purpose and it could, in the future, be an invaluable tool 
in the reduction of risk with direct cost savings to the NHS and indirect cost reductions to patients 
and carers. This would require further cost-effectiveness analysis. Nonetheless, the ERA scale should 
be considered as part of the toolkit of the clinician in assessing the daily lives of people with 
epilepsy. 
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